RT Journal Article
SR Electronic
T1 Steroidal Therapy plus Conventional Therapy versus Conventional Therapy alone for Tuberculous Meningitis: A systematic review and Meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.05.24312952
DO 10.1101/2024.09.05.24312952
A1 Naseem, Ansa
A1 Javed, Muhammad Moiz
A1 Rehmani, Malaika
A1 Tariq, Muhammad Haider
A1 Sikandar, Mahnoor
A1 Ejaz, Usama
A1 Bajwa, Muhammad Shahzaib
A1 Raza, Tehseen
A1 Khan, Muhammad Usman
A1 Shehram, Ali
A1 Khan, Muhammad Hammad
A1 Ayyan, Muhammad
A1 Luqman, Muhammad
YR 2024
UL http://medrxiv.org/content/early/2024/09/06/2024.09.05.24312952.abstract
AB Background Tuberculosis meningitis (TBM) is the most severe form of extrapulmonary tuberculosis with a high rate of morbidity and mortality. Treatments for TBM include conventional therapy alone as well as adjunctive use of steroidal therapy.Methods A comprehensive search of electronic databases such as PubMed, Cochrane, and Scopus was conducted from inception to April 2024 to retrieve all randomized controlled trials (RCTs) that compared steroidal therapy plus conventional antituberculosis therapy with antituberculosis therapy alone for patients of TBM. Meta-analysis was performed using Review Manager 5.4. Dichotomous outcomes were compared using risk ratio (RR).Results There was a statistically significant decrease in risk of mortality in the Steroid group compared to the control group (RR 0.84; 95% CI 0.75, 0.94; p-value < 0.05). However, there was no statistically significant difference in the risk of neurological deficit between the two groups. There was a statistically significant reduction in the risk of adverse events in the steroidal therapy group compared to the control group (RR 0.90; 95% CI 0.83, 0.98; p-value = 0.03). Similarly, there was a significant improvement in the clinical efficacy in the steroidal therapy group compared to the control (RR 1.16; 95% CI 1.02, 1.31; p-value = 0.02).Conclusion Steroids in addition to antituberculosis therapy significantly reduce mortality and adverse events, while improving clinical outcomes in patients of TBM. There is a need for controlled studies with longer follow-up durations to improve the robustness of the results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study received no funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData is available upon reasonable request to the authors.